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Nonvalvular atrial ﬁbrillation (AF) is a risk factor for stroke in elderly patients. Although warfarin
has been used to prevent AF-associated stroke for more than 50 years, non–vitamin K antago-
nist oral anticoagulants (NOACs) including dabigatran, rivaroxaban, apixaban, and edoxaban
recently have been developed to overcome the disadvantages of warfarin. Based on the results
of NOAC clinical trials, Savelieva and Camm made recommendations regarding selection of
NOACs in patients with nonvalvular AF. Recent accumulating evidence indicates that NOACs
work differently in Asian and non-Asian individuals. In this review, we discuss the results of the
large, randomized, phase 3 international clinical trials on NOACs, the subanalyses of Asians,
and a Japanese phase 3 clinical trial of rivaroxaban to discriminate Japanese patient–speciﬁc
characteristics with regard to their responses to NOACs and make recommendations. Our anal-
ysis revealed that rivaroxaban decreased the incidence of gastrointestinal (GI) bleeding com-
pared with warfarin in Japanese patients. The efﬁcacy results showed that rivaroxaban
signiﬁcantly decreased the incidence of ischemic stroke (hazard ratio: 0.40, 95% conﬁdence
interval: 0.17-0.96) compared with warfarin. The lower incidence of GI bleeding and ischemic
stroke may be speciﬁc to Japanese patients. Based on the present and previous results, the fol-
lowing recommendations regarding the selection of NOACs are added in the Camm chart for
Japanese patients: edoxaban for patients with a high risk of bleeding and those with a previous
stroke; and rivaroxaban for patients with a high risk of ischemic stroke and a low bleeding risk,
and those with previous GI bleeding.
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1 | INTRODUCTION
Nonvalvular atrial ﬁbrillation (AF) is known as a risk factor for stroke.
It was reported that approximately 20% of hospitalized patients with
ischemic stroke in Japan had AF complications.1 Warfarin has been
used to prevent AF-associated stroke for more than 50 years, but
warfarin treatment is a burden for patients and physicians because it
requires a dose adjustment achieved by monitoring the prothrombin
time–international normalized ratio (PT-INR). Warfarin also interacts
with food and many other drugs.
Non–vitamin K antagonist oral anticoagulants (NOACs) were
developed to overcome these disadvantages of warfarin, and the efﬁ-
cacy and safety of NOACs have been tested in comparative studies
with warfarin as a control. In recent years, several NOACs have
become available. Based on the results of phase 3 clinical trials, Save-
lieva and Camm presented a chart (the Camm chart) to help physi-
cians choose the best available NOAC in light of each patient’s
condition.2 However, because the chart was created based on the
results of international collaborative clinical trials, it must be used
carefully for Japanese patients.
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First, the therapeutic range of warfarin’s PT-INR for Japanese
patients is different from that for patients in other countries. The
range of 1.6 to 2.6 is recommended for Japanese elderly patients
(age ≥70 years), whereas a range of 2.0 to 3.0 is recommended in the
EU and US guidelines.3 This difference in the therapeutic range in
INR is based on the higher incidence of warfarin-related intracranial
hemorrhage (ICH) in Asians, including Japanese.4
Based on the present review, therefore, we propose a method
for selecting NOACs for Japanese patients with AF based on the
results of subanalyses of Asian patients in the following clinical trials:
Randomized Evaluation of Long-term Anticoagulation Therapy (RE-
LY),5 Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Com-
pared with Vitamin K Antagonism for Prevention of Stroke and
Embolism Trial in Atrial Fibrillation (ROCKET AF),6 and Apixaban for
Reduction in Stroke and Other Thromboembolic Events in Atrial
Fibrillation (ARISTOTLE),7 as well as the Japanese–ROCKET AF (J-
ROCKET AF) study in which Japanese patients participated.8
Edoxaban was approved for stroke prevention in patients with AF
(SPAF) in 2014 in Japan, and it is not yet included in the Camm chart. In
the present review, we discuss the characteristics, efﬁcacy, and safety of
edoxaban and 3 other NOACs: dabigatran, rivaroxaban, and apixaban.
2 | CHARACTERISTICS OF THE NOACS
The characteristics of the 4 NOACs (edoxaban, dabigatran, rivaroxa-
ban, and apixaban) have been compared with those of warfarin and
reported in numerous studies.9–16 In brief, NOACs have shorter half-
lives and take less time to reach maximum blood concentration than
does warfarin. Unlike warfarin, NOACs have a speciﬁc target (either
thrombin or factor Xa), do not require coagulation monitoring, and
can be administered with ﬁxed doses.
3 | EVIDENCE FROM INTERNATIONAL
CLINICAL TRIALS
The summary of key patient characteristics and ﬁndings from the
4 phase 3 clinical trials of NOACs are described in previous
studies,17–21 and major differences are also summarized in the Table
1. Unlike the other 3 clinical trials, the ROCKET AF study included
patients with a moderate to high risk of stroke that resulted in a
higher ischemic stroke risk (CHADS2 score), higher proportion of
patients with a history of stroke or TIA, and a lower time in therapeu-
tic range (TTR) for INR in the ROCKET AF study (Table 1).17 In the
ROCKET AF study, the noninferiority of rivaroxaban compared with
warfarin was demonstrated in the incidence of stroke or systemic
embolism (SE; hazard ratio [HR]: 0.88, 95% conﬁdence interval [CI]:
0.75-1.03, P = 0.12) in the intention-to-treat population (Table 1).17
The results of the Anti-Xa Therapy to Lower Cardiovascular Events in
Addition to Standard Therapy in Subjects with Acute Coronary
Syndrome–Thrombolysis in Myocardial Infarction 51 (ATLAS ACS2-
TIMI51) study showed that rivaroxaban is effective in reducing the
risk of the composite endpoint of death from cardiovascular causes,
myocardial infarction, or stroke in patients with recent acute coronary
syndrome (ACS).22 The results of the ROCKET AF study also showed
that the incidence of major bleeding from a gastrointestinal (GI) site
in the rivaroxaban group (3.2%) was signiﬁcantly higher than that in
the warfarin group (2.2%) (P < 0.001). In addition, the incidence of
major bleeding in the rivaroxaban group relative to the warfarin
group tended to be higher (HR: 1.04, 95% CI: 0.90-1.20, P = 0.58)
compared with the other 3 NOACs.
In the Effective Anticoagulation with Factor Xa Next Generation
in Atrial Fibrillation–Thrombolysis in Myocardial Infarction
48 (ENGAGE AF-TIMI 48) study,18 the noninferiority of edoxaban at
30 mg qd (HR: 1.13, 97.5% CI: 0.96-1.34, P = 0.10) and 60 mg qd
TABLE 1 Key patient characteristics and ﬁndings from the phase 3 trials of the non–vitamin K antagonist oral anticoagulants vs warfarin
RE-LY19,20 ROCKET AF17 ARISTOTLE21 ENGAGE AF-TIMI 4818
NOAC examined Dabigatran Rivaroxaban Apixaban Edoxaban
Mean CHADS2 score 2.1 3.5 2.1 2.8
Prior stroke/TIA, % 20 55 19 28
NOAC dosing arm 110 mg bid 150 mg bid 20 mg qd 5 mg bid 30 mg qd 60 mg qd
HR (95% CI) for NOAC vs warfarin
Stroke or SE (ITT population) 0.90 (0.74-1.10) 0.65 (0.52-0.81) 0.88 (0.75-1.03) 0.79 (0.66-0.96) 1.13 (0.96-1.34) 0.87 (0.73-1.04)
Ischemic stroke 1.11 (0.89-1.40) 0.76 (0.60-0.98) 0.94 (0.75-1.17) 0.92 (0.74-1.13) 1.41 (1.19-1.67) 1.00 (0.83-1.19)
Major bleeding 0.80 (0.70-0.93) 0.93 (0.81-1.07) 1.04 (0.90-1.20) 0.69 (0.60-0.80) 0.47 (0.41-0.55) 0.80 (0.71-0.91)
ICH 0.30 (0.19-0.45) 0.41 (0.28-0.60) 0.67 (0.47-0.93) 0.42 (0.30-0.58) 0.30 (0.21-0.43) 0.47 (0.34-0.63)
GI bleeding 1.10 (0.86-1.41) 1.50 (1.19-1.89) Not calculated HR1 0.89 (0.70-1.15) 0.67 (0.53-0.83) 1.23 (1.02-1.50)
MI 1.29 (0.96-1.75) 1.27 (0.94-1.71) 0.81 (0.63-1.06) 0.88 (0.66-1.17) 1.19 (0.95-1.49) 0.94 (0.74-1.19)
Death 0.91 (0.80-1.03) 0.88 (0.77-1.00) 0.85 (0.70-1.02) 0.89 (0.80-0.99) 0.87 (0.79-0.96) 0.92 (0.83-1.01)
Abbreviations: ARISTOTLE, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation; bid, twice daily; CHADS2, conges-
tive HF, HTN, age ≥75 years, DM, stroke or TIA (2 points); CI, conﬁdence interval; DM, diabetes mellitus; ENGAGE AF-TIMI 48, Effective Anticoagulation
with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48; GI, gastrointestinal; HF, heart failure; HR, hazard ratio;
HTN, hypertension; ICH, intracranial hemorrhage; ITT, intention to treat; MI, myocardial infarction; NOAC, non-vitamin K antagonist oral anticoagulant;
qd, once daily; RE-LY, Randomized Evaluation of Long-term Anticoagulation Therapy; ROCKET AF, Rivaroxaban Once Daily Oral Direct Factor Xa Inhibi-
tion Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation; SE, systemic embolism; TIA, transient ische-
mic attack; TTR, time in therapeutic range for international normalized ratio.
HRs are for the NOAC group as compared with the warfarin group.
1Major bleeding from GI site: 224 bleeding events (3.2%) in the rivaroxaban group, as compared with 154 events in the warfarin group (2.2%; P < 0.001).
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(HR: 0.87, 97.5% CI: 0.73-1.04, P = 0.08) for decreasing the incidence
of stroke or SE compared with warfarin was reported. However, the
HR at 30 mg qd was slightly higher than that at 60 mg qd. The results
further showed that edoxaban signiﬁcantly lowered the incidence of
major bleeding and ICH at 30 mg qd (major bleeding HR: 0.47, 95%
CI: 0.41-0.55, P < 0.001; ICH HR: 0.30, 95% CI: 0.21-0.43,
P < 0.001) and 60 mg qd (major bleeding HR: 0.80, 95% CI: 0.71-
0.91, P < 0.001; ICH HR: 0.47, 95% CI: 0.34-0.63, P < 0.001) com-
pared with warfarin. On the other hand, it also signiﬁcantly increased
the incidence of GI bleeding at 60 mg qd (HR: 1.23, 95% CI: 1.02-
1.50, P = 0.03) and that of ischemic stroke at 30 mg qd (HR: 1.41,
95% CI: 1.19-1.67, P < 0.001).
Dabigatran at 150 mg bid was superior to warfarin in decreasing
the incidence of stroke or SE (P < 0.001), and it was noninferior to
warfarin at 110 mg bid (HR: 0.90, 95% CI: 0.74-1.10, P = 0.30).19,20
Although dabigatran at 150 mg bid signiﬁcantly lowered the incidence
of ischemic stroke compared with warfarin (HR: 0.76, 95% CI: 0.60-
0.98, P = 0.03), dabigatran at 110 mg bid did not (HR: 1.11, 95% CI:
0.89-1.40, P = 0.35). Overall, dabigatran at 110 mg bid signiﬁcantly
lowered the incidence of major bleeding compared with warfarin
(P = 0.003); however, when the bleeding incidence is analyzed by
bleeding sites, dabigatran increased the incidence of GI bleeding both
at 110 mg bid (HR: 1.10, 95% CI: 0.86-1.41, P = 0.43) and 150 mg bid
(HR: 1.50, 95% CI: 1.19-1.89, P < 0.001). The incidence of GI bleeding
with dabigatran 150 mg bid was highly increased.
The ARISTOTLE study showed that apixaban signiﬁcantly
reduced the incidence of stroke or SE compared with warfarin
(P = 0.01).22 Apixaban also signiﬁcantly reduced the incidence of both
major bleeding (HR: 0.69, 95% CI: 0.60-0.80, P < 0.001) and ICH
(HR: 0.42, 95% CI: 0.30-0.58, P < 0.001). The noninferiority of apixa-
ban to warfarin regarding GI bleeding (HR: 0.89, 95% CI: 0.70-1.15,
P = 0.37) was also shown in the ARISTOTLE study.
4 | FINDINGS FROM SUBANALYSES OF
ASIANS FROM THE INTERNATIONAL
CLINICAL TRIALS
The proportion of Asian patients with a history of stroke was higher
than that of non-Asian patients.23 Three NOACs (dabigatran, rivarox-
aban, and apixaban) and warfarin showed a higher incidence of stroke
in Asians compared with non-Asians (Figure 1A,B), suggesting that
stroke occurs more often in Asians. Warfarin also increased the inci-
dence of major bleeding in Asians compared with non-Asians, but
3 NOACs reduced major bleeding more in Asians than non-Asians
(Figure 1C,D), indicating that warfarin tends to cause major bleeding
FIGURE 1 Ethnic differences in the incidence of stroke or systemic embolism and major bleeding.5–7 (A) Incidence of stroke or systemic
embolism in Asian populations. (B) Incidence of stroke or systemic embolism in Non-Asian populations. (C) Incidence of major bleeding in Asian
populations. (D) Incidence of major bleeding in Non-Asian populations. Abbreviations: ARISTOTLE, Apixaban for Reduction in Stroke and Other
Thromboembolic Events in Atrial Fibrillation; bid, twice a day; D110, dabigatran 110 mg bid; D150/R20/A5, dabigatran 150 mg bid/rivaroxaban
20 mg qd/apixaban 5 mg bid; qd, once a day; RE-LY, Randomized Evaluation of Long-term Anticoagulation Therapy; ROCKET AF, Rivaroxaban
Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial
Fibrillation.
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in Asians. The incidence of ICH in Asians was higher with any of the
drugs tested than that in non-Asians; however, whereas warfarin
increased the ICH incidence 3-fold, the 3 NOACs doubled the inci-
dence.5–7 These studies supported the results of previous epidemio-
logical studies, in which an increased incidence of warfarin-related
ICH was shown in Asian populations.4
5 | FINDINGS FROM THE JAPANESE
PHASE 3 CLINICAL TRIAL
There are 2 important differences between the J-ROCKET AF and
ROCKET AF studies.8 First, the rivaroxaban dose in the J-ROCKET
AF study (15 mg qd) was lower than that in the EU and US (20 mg
qd), because the pharmacokinetic data (Cmax, area under the curve) of
rivaroxaban in Japanese patients who received rivaroxaban at 15 mg
qd were observed to be comparable with those of Caucasian patients
who received rivaroxaban at 20 mg qd.24 For Japanese patients, the
dose is further reduced to 10 mg qd if renal function is impaired (with
a creatinine clearance of 30–49 mL/min). Second, in the J-ROCKET
AF study, warfarin with the INR 1.6 to 2.6 is recommended in
patients age ≥70 years, as in the Japanese guideline,3 instead of the
INR of 2.0 to 3.0 as used in the European Union and United States.
In the J-ROCKET AF study, the safety data showed that there
was no signiﬁcant difference between rivaroxaban and warfarin in
the incidences of major bleeding (HR: 0.85, 95% CI: 0.50-1.43) or
death caused by bleeding (HR: 0.33, 95% CI: 0.03-3.14).8 However,
when the results were analyzed by the bleeding site, several advan-
tages were found in Japanese patients, including that rivaroxaban
decreased the incidence of GI bleeding by approximately 50% com-
pared with warfarin. Because the incidence of GI bleeding (P < 0.001)
was lower in the warfarin group than in the rivaroxaban group in the
global clinical trial ROCKET AF study, the lower GI bleeding in the
rivaroxaban group appears to be speciﬁc to Japanese patients
(Figure 2). Rivaroxaban also decreased the ICH rate in Japanese
patients compared with warfarin (rivaroxaban 0.65%/y, warfarin
1.32%/y). It should, however, be noted that the possibility of a lack
of robustness of the outcome analysis in the J-ROCKET AF study
FIGURE 2 Major bleeding rates by sites in
the J-ROCKET AF and ROCKET AF
studies.8,18 Abbreviations: GI,
gastrointestinal; GIT, gastrointestinal tract;
J-ROCKET AF, Japanese ROCKET AF;
ROCKET AF, Rivaroxaban Once Daily Oral
Direct Factor Xa Inhibition Compared with
Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial
Fibrillation.
FIGURE 3 Considerations when selecting
a NOAC for Japanese patients. NOACs
recommended for Japanese patients but
not included in the original Camm chart are
highlighted in red. Abbreviations: ACS,
acute coronary syndrome; bid, twice a day;
CAD, coronary artery disease; GI,
gastrointestinal; HAS-BLED, hypertension,
abnormal renal/liver function, stroke,
bleeding history or predisposition, labile
international normalized ratio, elderly (age
≥65 years), drugs/alcohol concomitantly;
MI, myocardial infarction; NOAC, non-
vitamin K antagonist oral anticoagulant; qd,
once a day.
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could not be excluded because of the small sample size of the Japa-
nese cohort used in the study.8
Although difference in the primary efﬁcacy endpoint (all-cause
stroke plus non–central nervous system SE; HR: 0.49, 95% CI: 0.24-
1.00, P = 0.050) was not signiﬁcant, rivaroxaban signiﬁcantly
decreased the incidence of all-cause stroke (HR: 0.46, 95% CI: 0.22-
0.98) compared with warfarin.8,25 Rivaroxaban also signiﬁcantly
decreased the incidence of ischemic stroke (HR: 0.40, 95% CI: 0.17-
0.96) compared with warfarin in Japanese patients, whereas in the
global ROCKET AF study, the incidence data were HR: 0.94 and 95%
CI: 0.75-1.17, suggesting that the lower incidence in ischemic stroke
with rivaroxaban may be speciﬁc to Japanese patients.
6 | RECOMMENDATIONS FOR THE
SELECTION OF NOACS IN JAPAN
Since edoxaban was approved for SPAF in 2014 in Japan, we
reviewed the results of the ENGAGE AF-TIMI 48 study and the
phase 3 Japanese study (J-ROCKET AF study) to investigate whether
there are any Japanese-speciﬁc traits in the Camm chart.2 Based on
the results, we propose the following Japanese version of the Camm
chart (Figure 3).
In the Japanese version of the Camm chart, rivaroxaban is
excluded from administration to patients with a high risk of bleeding
(ie, a HAS-BLED score ≥3) because it did not signiﬁcantly decrease
the incidence of major bleeding (HR: 1.04, 95% CI: 0.90-1.20,
P = 0.58) compared with warfarin.17 Instead, apixaban (HR: 0.69,
95% CI: 0.60-0.80, P < 0.001), dabigatran 110 mg bid (HR: 0.80, 95%
CI: 0.70-0.93, P = 0.03) and edoxaban (30 mg qd: HR: 0.47, 95% CI:
0.41-0.55, P < 0.001; 60 mg qd: HR: 0.80, 95% CI: 0.71-0.91,
P < 0.001) are recommended for Japanese patients with a high risk
of bleeding because they signiﬁcantly reduced the incidence of major
bleeding compared with warfarin.18–21
Dabigatran treatment is recommended for patients with a high
risk of ischemic stroke and a low bleeding risk because dabigatran
150 mg bid signiﬁcantly decreased the incidence of ischemic stroke
compared with warfarin in the RE-LY study (HR: 0.76, 95% CI: 0.60-
0.98, P = 0.03).19 For Japanese patients, rivaroxaban is also included
in the Japanese version of the Camm chart because it decreased the
incidence of ischemic stroke by 60% compared with warfarin in the
J-ROCKET AF study (HR: 0.40, 95% CI: 0.17-0.96).8
Based on the results of the ROCKET AF and the ENGAGE AF-
TIMI 48 studies, in which 55% and 28%, respectively, of the partici-
pants had a history of stroke,17,18 rivaroxaban and edoxaban are
recommended for patients with a previous stroke. Apixaban is also
recommended because it signiﬁcantly decreased the recurrence of
stroke (HR: 0.71, 95% CI: 0.51-0.97) in the ARISTOTLE subanalysis
of stroke recurrence prevention.26
Rivaroxaban is also recommended for patients with coronary
artery disease, a previous myocardial infarction (MI), or a high risk for
ACS/MI, as the results of the ATLAS ACS2-TIMI51 study showed
that rivaroxaban signiﬁcantly decreased the rate of death due to car-
diovascular events, MI, and stroke compared with placebo (HR: 0.84,
95% CI: 0.74-0.96, P = 0.008).22 However, rivaroxaban doses tested
in ATLAS ACS2-TIMI 51 were lower than therapeutic doses for pre-
vention of AF-related stroke (2.5/5.0 mg bid vs 15/20 mg qd) and
patients with AF were excluded. Thus, ﬁndings from ATLAS ACS2-
TIMI 51 may have the limited relevance to the prevention of stroke
in AF patients with high risk for ACS. On the other hand, dabigatran
and apixaban are not recommended for these patients because they
did not show the beneﬁt in previous randomized controlled studies
of dabigatran and apixaban in patients with ACS.27,28 In addition, the
RE-LY study failed to show the noninferiority of dabigatran to warfa-
rin in MI (110 mg bid: HR: 1.29, 95% CI: 0.96-1.75; 150 mg bid: HR:
1.27, 95% CI: 0.94-1.71).19,20 Edoxaban is also not recommended for
patients with coronary artery disease, previous MI, or high risk for
ACS/MI because of insufﬁcient evidence.
Dabigatran is not recommended for patients with GI disorders
because it causes dyspepsia in 11% to 12% of patients.19 When
patients have a history of recent or inadequately managed GI bleed-
ing or are at high risk for GI bleeding, apixaban, which decreased GI
bleeding (HR: 0.89, 95% CI: 0.70-1.15, P = 0.37)21 may be preferred.
Edoxaban 30 mg qd signiﬁcantly decreased GI bleeding in the
ENGAGE AF-TIMI 48 study. However, the recommended dose of
edoxaban is 60 mg qd, which is reduced to 30 mg qd depending on
renal function or concomitant drugs. Therefore, edoxaban 30 mg qd
is not recommended for patients with previous GI bleeding or high
risk for GI bleeding. In contrast, for Japanese patients, rivaroxaban is
included in the Japanese version of the Camm chart because the
results of the J-ROCKET AF study showed that rivaroxaban
decreased GI bleeding by approximately 50% compared with
warfarin.8
For patients with renal impairment, apixaban at 2.5 mg bid and
rivaroxaban at 10 mg qd would be more appropriate because the
respective renal clearances were 27% and 35%.12 At present, edoxa-
ban is not included in the Japanese version of the Camm chart
because the relevant data are not yet published.
7 | CONCLUSION
In Japan, 4 NOACs—dabigatran, rivaroxaban, apixaban, and
edoxaban—are currently approved for SPAF. It is important to under-
stand the differences between these NOACs and warfarin to maxi-
mize the beneﬁt of NOACs in patients with AF. Savelieva and Camm
made recommendations on the selection of NOACs (dabigatran, rivar-
oxaban, and apixaban) depending on patient characteristics.2 How-
ever, because studies have found that the stroke incidence and
bleeding incidence caused by warfarin and NOACs in Japanese
patients differ from those in non-Japanese patients, a Japanese ver-
sion of the Camm chart is proposed in this report, based on the clini-
cal trial data. At this time, postmarketing surveillance of rivaroxaban
in Japan shows no notable difference in safety and efﬁcacy compared
with the ﬁndings from the previous clinical trials.29 Currently ongoing
Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation
(XANTUS) studies in different regions of the world, in which safety
and efﬁcacy data on the use of rivaroxaban for stroke prevention in
AF in routine clinical practice are collected, are expected to further
provide ethnicity-speciﬁc differences.30
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